17 Jan SAHPRA clarifies the benefits and risks of medroxyprogesterone acetate
Pretoria, 17 January 2025 – The South African Health Products Regulatory Authority (SAHPRA) has recommended that the product information of medroxyprogesterone acetate (MPA)-containing products be amended by updating the safety warnings to include the potential risk of meningioma. MPA is a synthetic oral and injectable form...